Table 2 Immunological markers of the patients at presentation and at follow-up

Immunophenotyping

CD45/CD3 (1200–2600/mm³)

2397

3257

1617

CD45/CD3/CD4 (650–1500/mm³)

1018

2079

1062

CD45/CD3/CD8 (370–1100/mm³)

1167

1051

499

CD45 (3600–9800/mm³)

6968

1200

CD45/CD19 (720–2600/mm³)

1553

3133

0

CD45/CD3⁻/CD16⁺ (100–480/mm³)

153

277

80

Lymphocyte proliferation

Phytohemagglutinin (SI) (18.28–343.00)

25

33.0

61.2

Pokeweed (SI) (8.42–107.40)

7.0 ↓

35.2

11.5

OKT3 (SI) (15.62–219.30)

21

7.6 ↓

26.2

Cytomegalovirus (SI) (3.04–56.6)

ND

2.3 ↓

3.1

Response to vaccination

Anti-HBs

ND

↓

↓

Anti-tetanus

ND

↓

↓

Anti-pneumo 23 antibodies

ND

↓

↓

Immunoglobulins

IgG (232–1411 mg/dL)

2940

1734

42

IgM (19–145 mg/dL)

118

39

29

IgA (0–83 mg/dL)

155

31

< 7

IgE (0–24 K/U/L)

289

55

< 7

IgG subclasses

IgG1 (1700–9500 mg/L)

ND

4710

266

IgG2 (215–4400 mg/L)

ND

544

89

IgG3 (134–694 mg/L)

ND

310

99

IgG4 (4–1200 mg/L)

ND

210

21